Dr Reddys Laboratories (RDY) Non Operating Interest Expenses (2009 - 2026)

Dr Reddys Laboratories has reported Non Operating Interest Expenses for 18 years, with the latest figure at -$13.3 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 36.69% year-over-year to -$13.3 million in Q2 2026; TTM through Jun 2026 was $2.0 billion, a 215.08% increase from a year earlier, with the FY2026 full-year figure at -$40.0 million, down 19.5% from the prior year.
• Non Operating Interest Expenses was -$13.3 million for Q2 2026 at Dr Reddys Laboratories, down from $1.1 billion in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $1.1 billion in Q1 2026, with the low at -$15.0 million in Q2 2023.
• Average Non Operating Interest Expenses over 5 years is $141.2 million, with a median of -$7.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses slumped 313.51% in 2023, then surged 9843.87% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at -$10.0 million in 2022, then soared by 52.68% to -$4.7 million in 2023, then sank by 104.74% to -$9.7 million in 2024, then jumped by 9843.87% to $944.0 million in 2025, then slumped by 101.4% to -$13.3 million in 2026.
• The last three Non Operating Interest Expenses figures came in at -$13.3 million (Q2 2026), $1.1 billion (Q1 2026), and $944.0 million (Q4 2025), per Business Quant data.